Literature DB >> 3361537

A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): the value of a simple cutaneous classification in the early stages of the disease.

A J Barnett1, M H Miller, G O Littlejohn.   

Abstract

A longitudinal study was carried out on 177 patients with scleroderma between 1953 and 1983. Patients were classified into 3 types according to the extent of skin sclerosis within one year of presentation: Type 1 with sclerodactyly only; Type 2, skin stiffness proximal to the metacarpophalangeal joints but sparing the trunk; and Type 3, diffuse skin stiffness including the trunk. Ten year survival was 71% in Type 1, 58% in Type 2 and 21% in Type 3. Quality of life was best in Type 1, intermediate in Type 2 and worst in Type 3. Nailfold capillary abnormalities did not discriminate between the types, but anticentromere antibody correlated strongly with Type 1. The simple subdivision of scleroderma based on the early extent of clinical skin involvement has been found to be useful in predicting longterm outcome in this highly variable disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3361537

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  34 in total

1.  European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres.

Authors:  A Della Rossa; G Valentini; S Bombardieri; W Bencivelli; A J Silman; S D'Angelo; M M Cerinic; J F Belch; C M Black; R Becvar; P Bruhlman; F Cozzi; L Czirják; A A Drosos; B Dziankowska; C Ferri; A Gabrielli; R Giacomelli; G Hayem; M Inanc; N J McHugh; H Nielsen; R Scorza; E Tirri; F H van den Hoogen; P G Vlachoyiannopoulos
Journal:  Ann Rheum Dis       Date:  2001-06       Impact factor: 19.103

Review 2.  Rheumatology.

Authors:  R A Asherson; R Cervera; D P D'Cruz; G R Hughes
Journal:  Postgrad Med J       Date:  1991-02       Impact factor: 2.401

Review 3.  Scleroderma and survival.

Authors:  A J Silman
Journal:  Ann Rheum Dis       Date:  1991-04       Impact factor: 19.103

4.  Predictors of survival in 171 patients with systemic sclerosis (scleroderma).

Authors:  Z Nagy; L Czirják
Journal:  Clin Rheumatol       Date:  1997-09       Impact factor: 2.980

Review 5.  Epidemiology of scleroderma.

Authors:  A J Silman
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

6.  What does the clinician need to improve patient care in systemic sclerosis?

Authors:  Madelon C Vonk; Frank H J van den Hoogen; Piet L C M van Riel; Gabriele Valentini
Journal:  Ann Rheum Dis       Date:  2007-09       Impact factor: 19.103

7.  Guidelines on the use of extracorporeal photopheresis.

Authors:  R Knobler; G Berlin; P Calzavara-Pinton; H Greinix; P Jaksch; L Laroche; J Ludvigsson; P Quaglino; W Reinisch; J Scarisbrick; T Schwarz; P Wolf; P Arenberger; C Assaf; M Bagot; M Barr; A Bohbot; L Bruckner-Tuderman; B Dreno; A Enk; L French; R Gniadecki; H Gollnick; M Hertl; C Jantschitsch; A Jung; U Just; C-D Klemke; U Lippert; T Luger; E Papadavid; H Pehamberger; A Ranki; R Stadler; W Sterry; I H Wolf; M Worm; J Zic; C C Zouboulis; U Hillen
Journal:  J Eur Acad Dermatol Venereol       Date:  2014-01       Impact factor: 6.166

8.  Predictors of inpatient mortality in patients with systemic sclerosis: a case control study.

Authors:  Shiv T Sehra; Andrew Kelly; Joshua F Baker; Chris T Derk
Journal:  Clin Rheumatol       Date:  2016-04-07       Impact factor: 2.980

9.  Clinical setting of patients with systemic sclerosis by serum autoantibodies.

Authors:  U Picillo; S Migliaresi; M R Marcialis; A M Ferruzzi; G Tirri
Journal:  Clin Rheumatol       Date:  1997-06       Impact factor: 2.980

10.  Detection of circulating soluble CD28 in patients with systemic lupus erythematosus, primary Sjögren's syndrome and systemic sclerosis.

Authors:  M Hebbar; P Jeannin; G Magistrelli; P-Y Hatron; E Hachulla; B Devulder; J-Y Bonnefoy; Y Delneste
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.